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Abstract
Background: Fascin is an actin-bundling protein that is absent from most normal epithelia yet is upregulated in multiple
forms of human carcinoma, where its expression correlates clinically with a poor prognosis. How fascin-1 transcription is
activated in carcinoma cells is largely unknown, although the hypothesis of regulation by b-catenin signaling has received
attention. The question is important because of the clinical significance of fascin expression in human carcinomas.
Methodology/Principal Findings: Through comparative genomics we made an unbiased analysis of the DNA sequence of
the fascin-1 promoter region from six mammalian species. We identified two regions in which highly conserved motifs are
concentrated. Luciferase promoter reporter assays for the human fascin-1 promoter were carried out in fascin-positive and -
negative human breast and colon carcinoma cells, and in human dermal fibroblasts that are constitutively fascin-positive. In
all fascin-positive cells, the region 2219/+114 that contains multiple highly conserved motifs had strong transcriptional
activity. The region 22953/21582 appeared to contain repressor activity. By examining the effects of single or multiple
point mutations of conserved motifs within the 2219/+114 region on transcriptional reporter activity, we identified for the
first time that the conserved CREB and AhR binding motifs are major determinants of transcriptional activity in human colon
carcinoma cells. Chromatin immunoprecipitations for CREB, AhR or b-catenin from extracts from fascin-positive or -negative
human colon carcinoma cells identified that CREB and AhR specifically associate with the 2219/+114 region of the FSCN1
promoter in fascin-positive colon carcinoma cells. An association of b-catenin was not specific to fascin-positive cells.
Conclusion: Upregulation of fascin-1 in aggressive human carcinomas appears to have a multi-factorial basis. The data
identify novel roles for CREB and AhR as major, specific regulators of FSCN-1 transcription in human carcinoma cells but do
not support the hypothesis that b-catenin signaling has a central role.
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Introduction
Abnormalities of the actin cytoskeleton make important
contributions to the ability of carcinoma cells to invade adjacent
tissue and metastasise via the blood or lymphatic systems to remote
body sites [1]. Many of the actin-associated proteins that are
reported to be upregulated in carcinomas, for example ezrin, are
also expressed in the corresponding normal epithelium [2], raising
uncertainty over their practicality as possible therapeutic targets.
In recent years, the actin-bundling protein fascin has emerged as a
functionally relevant mediator of carcinoma cell migration,
invasion and metastasis in cell culture and mouse models [3–8].
Fascin (also known as fascin-1; gene name FSCN1 in human and
Fscn1 in mouse) bundles F-actin into tightly packed parallel arrays
that contribute to cell migration by providing rigidity to filopodia
and microspikes [9]. Fascin is of considerable interest as a
biomarker or potential therapeutic target because it is not
expressed by simple epithelia and is low or absent in stratified
epithelia, yet is strongly upregulated in most forms of human
carcinoma [10–15]. Notably, in all forms of human carcinoma
examined to date, high tumour expression of fascin protein is of
clinical significance and is associated with a poor prognosis in
carcinomas of the lung, oesophagus, stomach, colon, breast and
kidney [5,11,12,14–17]. Fascin expression has also been correlated
with local lymph node metastasis and distant metastasis [12,16–
18].
Increased levels of fascin-1 transcript have been reported in
multiple human carcinomas (e.g. [10,13]). The mechanism by
which fascin-1 transcription is upregulated in carcinomas is not
understood. Normal mammalian cells with high levels of fascin-1
transcripts include dendritic cells and neuronal cells [19–21] and
initial analyses of mechanisms for transcriptional regulation have
been made in these cells. In human or mouse Langerhans and
dendritic cells, fascin is absent from immature cells and becomes
highly expressed during terminal differentiation; this process
involves increased levels of the fascin-1 transcript [22,23]. As a
structural component of dendrites, fascin contributes to the
antigen-presenting activity of mature dendritic cells [22,24]. A
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promoter reporter activity in mature mouse dendritic cells but not
in immature cells; similarly, a 3.1 kb 59 flanking region of human
fascin-1 specifically confers induction of reporters in mature human
dendritic cells and other non-transformed fascin-positive cells. No
transcriptional regulation activity was detected in the first intron or
39 untranslated region [25,26]. In NT2 human neuronal precursor
cells, the levels of FSCN1 transcript and protein increased during
retinoic acid-induced terminal differentiation. This effect depend-
ed on the transcriptional coactivator and histone acetyltransferase
CBP (cAMP response element binding protein (CREB)-binding
protein). However, the relevance of CBP to FSCN1 promoter
activity was not addressed in this study [27].
Dysregulation of the Wnt/b-catenin signalling pathway is a
frequent cause of tumour progression in colorectal carcinomas.
The transcriptional activity of b-catenin is mediated through its
interaction with members of the TCF/LEF (T cell factor/
lymphocyte enhancer-binding factor 1) family of DNA-binding
transcription factors [28]. There are conflicting reports on whether
the transcriptional activity of fascin-1 is regulated by b-catenin
signalling [3,8]. Grothey et al. [3] identified multiple candidate T
cell factor (TCF) binding sites in the (mouse) Fscn1 promoter, but
found no effect of either TCF or b-catenin over-expression on
Fscn1 promoter activity when tested in human MDA-MB-435
cells. In contrast, a later study demonstrated regulation of Fscn1
promoter reporter activity upon expression of either a stabilised b-
catenin or dominant-negative TCF4 in two human cell lines [8].
Because both of these studies focused on analysis of the mouse
fascin-1 promoter, it remains unclear whether FSCN1 could be a
direct target of b-catenin/TCF transcriptional regulation in
human carcinomas. Understanding the mechanisms of FSCN1
transcriptional regulation in human carcinoma cells is an
important question because it may lead to novel prognostic tools
for early identification of the most biologically aggressive
carcinomas, and/or potential novel therapeutic strategies to
reduce tumour metastasis through inhibition of fascin expression.
Here, we first took the unbiased approach of identifying
evolutionary conserved regions of the fascin-1 promoter region in
mammals by comparative genomics. We built on these data to
analyse experimentally the cis-acting mechanisms of FSCN1
transcriptional regulation in human colon and breast carcinoma
cells. Our novel findings demonstrate previously unidentified roles
of cAMP response element-binding protein (CREB) and the aryl
hydrocarbon receptor (AhR) in the regulation of fascin-1
transcription in human carcinoma cells.
Results
Phylogenetic analysis of conserved motifs in the 59
flanking region of mammalian fascin-1 genes
To identify evolutionarily conserved sequences in the 59 flanking
region of mammalian fascin-1 genes, we extracted 5.5 kb of DNA
sequence 59 to the ATG codon of the fascin-1 gene from the
genomes of human and five other mammals: Pan troglidytes, Macaca
mulatta, Canis lupus familiaris, Mus musculus and Rattus norvegicus. For
the rat and chimpanzee, a full sequence for the entire 5.5 kb
region is not yet available, thus our detailed analysis focused on a
2k b5 9 flanking region for which all six species could be fully
aligned. The chicken (as an example of an avian) could not be
included because this region of its genome is not yet sequenced
completely.
To examine sequence conservation across the 2 kb 59 flanking
regions, a TCOFFEE multiple sequence alignment was prepared
(Figure S1). The alignment demonstrated that the three primate
genome sequences are near identical throughout this region apart
from scattered individual single nucleotide differences and some
short additional sequences in the macaque. In contrast, the dog
and rodent sequences contained multiple nucleotide insertions and
/or deletions, resulting in multiple gap insertions throughout the
alignment (Figure S1). Overall, the sequence conservation between
the 59 flanking regions of human and rodent fascin-1 was much
lower than between the primates (for example, the human and
mouse sequences have 54.6% identity over the 2 kb region,
whereas human and macaque are 90.5% identical). The most
significant region of conservation across all six species was within a
200 bp region, 59 to and including the translational start site
(Figure S1).
For an independent second methodology, the six sequences
were analysed by phylogenetic footprinting with the algorithm
FootPrinter. This algorithm identifies the most conserved
nucleotide motifs within a set of homologous DNA sequences,
under the premise that functional regulatory elements are more
highly conserved under natural selection than non-functional
DNA sequences [29]. The ‘‘footprints’’ obtained demonstrated
complete conservation of multiple motifs within the 200 nucleotide
region 59 to the translational start site (Fig. 1, designated region A).
A second region that included a high density of well-conserved
motifs was located between 21200 and 21000 in the three
primate sequences (Fig. 1, designated region B). Within region B,
the same motifs were conserved in all six species, but, in agreement
with the gapping noted in the TCOFFEE alignment, the exact
positioning of the motifs relative to the start site was different in the
rodent and dog sequences compared to the primates. Further 59 to
region B (i.e., between 21876 to 21176), the three primate
sequences contained additional conserved motifs in near-identical
locations relative to the translational start site (Fig. 1A). The rodent
and dog sequences had different numbers and locations of
conserved motifs within this region (e.g., the absence of blue-
coded motifs in region 21676/21576, Fig. 1A).
Mapping FSCN1 transcriptional activity in fascin-positive
and fascin-negative human carcinoma cells
On the basis of the comparative genomic analysis, we
hypothesised that either or both of regions A and B might have
significant regulatory roles in controlling FSCN1 transcription in
human carcinoma cells. To test this idea, we generated a set of
luciferase reporter constructs to compare the activity of a 3.1 kb 59
flanking region of FSCN1 (comprising the region 22956/+114)
with truncation mutants that included or deleted either or both of
regions A and B, or separated these regions from the distal
conserved motifs. A CMV promoter-driven luciferase reporter was
included as a positive control and a promoter-less luciferase as a
negative control (Fig. 2).
The luciferase reporter activity of these constructs was tested in
cells derived from human colon and breast adenocarcinomas,
because fascin expression is strongly associated with a poor
prognosis in these carcinomas [14,15,17]. The human colon
adenocarcinoma cell line SW480 has high fascin expression,
whereas SW1222 has negligible expression [4,7]. T47D is a well-
differentiated, fascin-negative carcinoma cell line derived from an
invasive ductal carcinoma [30] and MDA-MB-231 is an invasive
breast carcinoma line [31] with moderate fascin expression
(Fig. 3A). For comparison with promoter activity in a normal cell
type, we examined human dermal fibroblasts (HDF) that are
constitutively fascin-positive. COS-7 green monkey kidney cells
were included for comparison as fascin-positive, [32], transformed
primate cell line of epithelial origin.
Fascin-1 in Carcinoma Cell
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FSCN1 promoter. When normalized relative to CMV promoter
activity, the highest reporter activity of the 3.1 kb FSCN1 promoter
was detected in SW480, that have the highest level of fascin
protein (Fig. 3B, 3G). SW1222 cells or T47D do not express fascin
protein, yet a low level of 3.1 kb FSCN1 promoter-luciferase
reporter activity was detected in these cells (Fig. 3C, 3D). MDA-
MB-231, COS-7 and HDF cells, with moderate expression of
fascin, had similar intermediate levels of luciferase reporter activity
(Fig. 3E–3G). The level of 3.1 kb FSCN1 reporter activity in COS-
7 cells appeared low as a ratio against CMV promoter activity
because of the very high level of CMV promoter activity in these
SV40-transformed cells (Fig. 3G).
With regard to the deletion mutants, in SW480 cells, the distal
59 flanking region 22952(D)/+114 activated less than half the
luciferase reporter activity of the 3.1 kb FSCN1 promoter (Fig. 3B).
A similar fold reduction in activity was observed in all other cell
lines tested (Fig. 3B–3F). In contrast, the reporter activity of the
21582/+114 region was equivalent to that of the 3.1 kb FSCN1
promoter in all the cells (Fig. 3). In all cells except T47D the
2219/+114 promoter fragment, that includes only conserved
region A, had significantly increased reporter activity compared to
the 3.1 kb FSCN1 promoter or the 21582/+114 region (Fig. 3;
p=0.0002 for SW480 cells). Further truncation to 250/+114,
thus deleting region A, dramatically reduced luciferase reporter
activity in SW480 and all the other cells (Fig. 3). Residual
luciferase reporter activity in the carcinoma cells was completely
abolished by deletion of an additional seven nucleotides: the
construct 243/+114 had the same negligible activity as a
promoterless luciferase reporter (Fig. 3). These results demon-
strated that positive regulatory sequence elements active in human
carcinoma and fibroblast cells are concentrated within the region
2219 to 243 of FSCN1.
Transcriptional activation by the 2219/+114 region of
FSCN1 depends on multiple DNA sequence elements
As demonstrated by the bioinformatics analyses, the region
2219/+114 is well- conserved in mammals (Figure S1), and
Figure 1. Identification of evolutionarily conserved motifs in the fascin-1 promoter region by phylogenetic footprinting analysis. A,
2 kb of genomic DNA sequence 59 to the translational start codon of fascin-1 was extracted from the indicated mammalian genomes and analysed for
conserved motifs by the FootPrinter algorithm. On each line, alignment blocks are indicated by thin coloured lines. The vertical bars indicate the
positions of motifs that are conserved across the genomes, with each category of motif identified in a different colour. Corresponding motifs in
different sequences are in the same colour. The numbering scheme is the same as that used in other figures, with the transcriptional start site in the
human genome as +1. Asterisk indicates the position of a TCF motif identified by the rVista algorithm that is conserved in the human, chimpanzee
and dog genomes. B, the DNA sequence and conserved motifs within Region A from the human genome. C, the DNA sequence and conserved motifs
within Region B from the human genome. In B and C, motifs are in the same colour code as in A. The larger the font the stronger the conservation of
the motif: the largest font indicates complete conservation in all six species.
doi:10.1371/journal.pone.0005130.g001
Figure 2. Schematic diagram of FSCN1 promoter-luciferase
reporter constructs. The scale bar indicates the FSCN1 59 flanking
region. The name of each construct corresponds to the 59 and 39
junctions within the FSCN1 promoter, relative to the proposed
transcriptional start site. The numbering scheme is the same as in
Fig. 1. Broad black lines indicate FSCN1 59 flanking regions; dashed line
represents an internal deletion. Thin black lines represent sequence
from pcDNA3.1, 59 to the firefly luciferase cDNA.
doi:10.1371/journal.pone.0005130.g002
Fascin-1 in Carcinoma Cell
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To identify candidate transcription factor binding motifs within
this region of FSCN1, DNA sequences from the six mammals
corresponding to 2219/+114 of human FSCN1 were analysed
individually by Match 1.0 Public and pairwise by rVista (see
Methods). Core candidate motifs identified with probability
scores .0.8 in human and at least one other species were
chosen for further experimental analysis. Overall, multiple
candidate transcription factor binding sites were identified that
m e tt h e s ec r i t e r i a( F i g .4 A ) .O ft h e s e ,o n l yt h eC R E Ba n dT C F
motifs were completely conserved across all six species and the
AhR motif was highly conserved (Fig. 4B). These motifs also
corresponded to conserved motifs identified by FootPrinter
(Fig. 1). Additional candidate motifs identified in the human
sequence included multiple USF or Pax-4 (paired box 4) sites, a
SREBP-1 (sterol regulatory element-binding protein1) site and
an AP-4 site (Fig. 4A). For clarity, we will refer to the motifs as
m o t i f s1t o9 ,w i t hm o t i f1b e i n gt h em o s t5 9 to the
transcriptional start site (Fig. 4A). With the exception of the
Pax-4 motif (motif 3), the additional motifs were conserved only
in primates, or, in the case of motifs 1 and 5, between human
and chimpanzee only.
To test the functional relevance of the candidate transcription
factor binding sites, point mutations were prepared to inactivate
each of the identified conserved motifs in the context of the 2219/
+114 FSCN1 luciferase reporter plasmid (Fig. 4A, Fig. 5A). The
luciferase reporter activity of the mutants was compared to that of
wild-type FSCN1 2219/+114 in SW480 cells (Fig. 5B). Mutation
of the candidate AhR binding motif (motif 6, Fig. 4A, Fig. 5A),
resulted in a significant (p=0.0305) reduction in transcriptional
reporter activity. Similarly, mutations of the candidate USF motif
(motif 7, p=0.03), the CREB binding motif (motif 8, p,0.0001),
or the TCF motif (motif 9, p=0.004) each resulted in significantly
reduced transcriptional reporter activity compared to wild-type
(Fig. 5B). In contrast, mutation of sites 1, 2, 3, 4 or 5 had no
statistically significant effect on luciferase reporter activity (Fig. 5B).
The general significance of these results was assessed by repeating
the analysis in COS-7 and MDA-MB-231 cells. Identical results
were obtained, with the exception of the TCF motif (motif 9), for
which the mutation did not reduce transcriptional reporter activity
in COS-7 cells (data not shown).
Because several of the point mutants decreased but did not
abolish transcriptional reporter activity in multiple cells, selected
combinatorial point mutants were generated and tested in SW480
cells. Double mutations of the BSAP and CREB motifs; USF and
CREB motifs, or the AP-1 and CREB motifs, did not further
decrease reporter activity compared to the CREB motif mutant
alone (Fig. 5B). In contrast, the combined mutation of the AhR
and CREB motifs inhibited transcriptional activity very strongly in
comparison to the individual mutations (p=,0.0001 vs the single
AhR mutant and p=0.0002 vs the single CREB mutant) (Fig. 5B).
It was not possible to combine the designed AhR and USF motif
mutations because the core motifs overlap extensively in the
nucleotide sequence (Fig. 4A).
In view that the double mutant of the AhR and CREB motifs
retained a low level of reporter activity, a number of triple point
mutants were tested. Combining the motif 1 mutant had only a
minor additional effect (Fig. 5B). Inclusion of either the SREB site
(motif 3) or AP-1 site (motif 8a) mutant with the AhR and CREB
motif mutants did not further decrease reporter activity (Fig. 5B).
However, inclusion of the AP-4 site (motif 4) mutant with the AhR
and CREB motif mutants resulted in a statistically significant
reduction of activity (Fig. 5B, p=0.02 vs the double AhR and
CREB motif mutant). Reporter activity was not further decreased
in a quadruple mutant that included the motif 1 mutation (Fig. 5B).
These experiments were repeated in COS-7 cells with identical
results (data not shown). These data identify the candidate AhR
and CREB motifs as major determinants of the transcriptional
activity of the FSCN1 2219/243 region.
Figure 3. FSCN1 promoter reporter activity in fascin-positive
and -negative cells. A, comparison of fascin protein levels in MDA-
MB-231 and T47D breast carcinoma cells. Whole cell extracts from the
equivalent of 4.5610
4 cells/lane were resolved on 10% SDS-PAGE gels
under reducing conditions, transferred to PVDF membrane and
immunoblotted with the indicated antibodies. b-actin was used as a
loading control. B–G, FSCN1 and CMV promoter activities were
analysed by dual luciferase reporter assays in the six indicated cells.
In each experiment, firefly luciferase activities were normalized against
Renilla luciferase activity. In each graph, the mean normalized CMV
promoter activity for that cell type is set as 1 and FSCN1 reporter
activities are expressed as a fraction of the CMV reporter activity. Each
column represents the mean from 3 independent experiments, bars
indicate s.e.m.
doi:10.1371/journal.pone.0005130.g003
Fascin-1 in Carcinoma Cell
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associated with the 2219/+7 region of FSCN1 in fascin-
positive human carcinoma cells
On the basis of the above experimental data, and the very
strong evolutionary conservation of the candidate CREB and AhR
binding motifs between the six mammals (Fig. 4B), we next
examined whether CREB and AhR specifically associate with the
endogenous FSCN1 promoter in human carcinoma cells. Immu-
noblot analyses with well-characterised antibodies demonstrated
that AhR and CREB were both expressed in all four of the
carcinoma cell lines (Fig. 6A). The molecular mass of AhR was
consistent with that reported in other studies [33,34]. Phosphor-
ylation of CREB at residue Ser-133 promotes recruitment of
coactivators needed for transcriptional activation [35], and there
was no detectable difference in the content of S133-phospho-
CREB in the four lines of fascin-positive or –negative human
carcinoma cells (Fig. 6A). The antibody used is a sensitive detector
of pCREB [36,37] and indeed differences in pCREB content were
apparent when additional cell lines were compared (shown for
Figure 4. Identification of candidate transcription factor binding sites in the 2219/+114 59 flanking region of FSCN1.A , The DNA
sequence of the 2219/+114 region of FSCN1 (from GenBank NC_000007.12). Candidate core motif binding sites for the indicated transcription factors
were identified with the Match 1.0 Public, rVISTA or Target explorer algorithms, in combination with evaluation of the evolutionary conservation of
the identified motifs in six mammals (see Figure S1 and Fig. 1). Motifs selected for mutagenesis are numbered 1–9 and are shown boxed. Nucleotide
substitutions introduced in the point mutants are shown below the sequence. Nucleotides corresponding to the TATA box and predicted
transcriptional start site are in bold. Restriction enzyme sites added for subcloning of the parent wildtype DNA are in bold and underlined. B, multiple
sequence alignment demonstrating the conservation of the AhR, CREB and TCF motifs (motifs 6, 8 and 9) in mammals.
doi:10.1371/journal.pone.0005130.g004
Fascin-1 in Carcinoma Cell
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pS133-CREB were located principally in the nuclei of SW1222
and SW480 cells (data not shown).
We used chromatin immunoprecipitation to examine whether
AhR and CREB are associated in SW480 cells with the
endogenous 59 flanking region 2219/+7o fFSCN1. Histone
binding to the promoter region of the glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) gene was used as a positive control (data
not shown). AhR and CREB were each reproducibly detected in
association with the 2219/+7 region of the endogenous FSCN1
promoter and were enriched relative to the negative control
immunoprecipitations (Fig. 6C). To examine whether these
associations were specific to fascin-positive carcinoma cells, the
analysis was extended to SW1222 cells. In immunoprecipitates
from chromatin extracts of SW1222 cells, no enrichment of AhR
nor CREB in association with the 2219/+7 region of the FSCN1
promoter was detectable relative to the negative control
imunoprecipitation (Fig. 6D). To confirm the specificity of
immunoprecipitation, the PCR products from the input samples
of both SW480 and SW1222 cells were sequenced: both DNAs
had exactly the same sequence that corresponded to the human
genome reference sequence for FSCN1 as shown in Fig. 4A.
To quantify the association of CREB and AhR with the 2219/
+7 region of the FSCN1 promoter in SW480 and SW1222 cells,
quantitative real-time PCR (qRT-PCR) was carried out. DNA
samples from chromatin immunoprecipitates from SW1222 and
SW480 cells were analysed in comparison to the respective input
DNA and DNA from negative control IgG immunoprecipitates,
all in the same sets of reactions. For the reactions from SW480
cells, the CREB and AhR immunoprecipitations, and GAPDH
used as a positive control, all resulted in significant enrichment of
the 2219/+7 promoter region relative to IgG control immuno-
precipitations (Fig. 6E). For the reactions from SW1222 cells, only
the GAPDH positive control was significantly enriched relative to
negative control immunoprecipitations. A small enrichment for
the AhR immunoprecipitations did not reach statistical signifi-
cance (p=0.38) (Fig. 6E).
These results demonstrate a correlation between the association
of CREB and AhR with the 2219/+7 region of the FSCN1
promoter and fascin protein expression in human colon carcinoma
cells.
Association of b-catenin with the 2219/+114 region of
human fascin-1 is not specific to fascin-positive
carcinoma cells
There are conflicting reports in the literature on the relevance of
b-catenin signaling for regulating fascin-1 promoter activity [3,8].
Figure 5. The transcriptional activity of FSCN1 2219/+114 promoter region is due to multiple sequence motifs. A, Schematic view of
the single and combined point mutations prepared in the FSCN1 2219/+114 luciferase reporter construct. In the top line, each numbered box
represents the correspondingly numbered motif, as shown in Fig. 4. The candidate transcription factor binding sites disrupted by each point
mutation are listed above each box. Each lower line represents a different construct; black boxes represent the mutated motifs. Not to scale. B,
Comparative analysis of the transcriptional activity of the point mutant FSCN1 2219/+114 promoter reporter constructs. All constructs were analysed
by luciferase reporter assay in SW480 cells, with normalization to Renilla luciferase activity. The mean normalized activity of wild-type FSCN1 2219/
+114 is set as 1 and the activities of the mutant constructs are expressed as a fraction of the wildtype. Each column represents the mean of 3 to 4
independent experiments, bars indicate s.e.m. Significant p values are stated in the text.
doi:10.1371/journal.pone.0005130.g005
Fascin-1 in Carcinoma Cell
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highly conserved in mammals and that mutation of this site
affected the transcriptional reporter activity of the 2219/+114
region in SW480 cells, we examined the possible association of b-
catenin with this region of the FSCN-1 promoter and its specificity.
By chromatin immunoprecipitation from SW480 extracts, the
2219/+114 region was specifically enriched in b-catenin
immunoprecipitates compared to negative control immunopre-
cipitates (Fig. 7A). However, the identical result was obtained with
chromatin immunoprecipitates prepared from fascin-negative
SW1222 cells (Fig. 7B). Furthermore, b-catenin was also found
to be specifically associated with the 2219/+114 region of the
FSCN1 promoter in fascin-negative Namalwa B lymphocyte cells
(data not shown). Thus, the association of b-catenin with the
2219/+114 region was not found to be specific to fascin-positive
human carcinoma cells. From the bioinformatic analyses, we had
identified a second candidate TCF binding motif that is conserved
in human, chimpanzee and dog (Fig. 1, position indicated by
asterisk). However, by chromatin immunoprecipitation, no specific
association of b-catenin with this region of the genome was
detected in either SW480 or SW1222 cells (Fig. 7C, 7D) relative to
the negative control immunoprecipitations. Collectively, these
data do not support the hypothesis that b-catenin has a specific
role in regulating FSCN1 transcriptional activity in fascin-positive
human carcinoma cells.
Discussion
Because fascin up-regulation correlates with poor prognosis and
metastatic progression in multiple human carcinomas, fascin is
emerging as an attractive potential therapeutic target. We
combined bioinformatic and experimental approaches to identify
motifs within the FSCN1 promoter that are of functional relevance
to the pathological expression of fascin in human carcinomas. By
comparing the fascin-1 promoter region from six mammalian
species, we obtained resolution for identification of candidate
regulatory motifs in the human fascin-1 promoter. Similarly,
distinctions between the human and mouse fascin-1 promoters that
have been obscure from analysis of either species could be
clarified. The central novel findings of our study are: a), the
identification of two separate regions within the 59 flanking region
of mammalian fascin-1 genes in which specific, highly conserved
sequence motifs are concentrated; b), the identification of a
combined action of the well-conserved CREB- and AhR-binding
motifs in positive transcriptional regulation of FSCN1, and c), the
identification that AhR and CREB transcription factors are
specifically associated with the FSCN1 promoter in fascin-positive
human colon carcinoma cells.
The availability of multiple sequenced mammalian genomes has
greatly increased possibilities for making broadly based, and
therefore more accurate, identification of evolutionarily conserved
features within the human genome. This is particularly important
for analyses of candidate transcription factor binding sites, for
which the core motifs are under 10 nucleotides long, and which
tend to be over-predicted by motif identification algorithms. With
the benefit of genomic sequences from six mammals for multiple
sequence alignment and motif analysis, we definitively identified
two separate major regions of very high sequence conservation
situated within 2 kb upstream of the translational start codon of
fascin-1. Both regions contain multiple conserved motifs located in
a conserved order, suggestive of important functional roles in
transcriptional regulation of fascin-1.
Indeed, through analysis of the activity of a set of promoter
reporter constructs we have demonstrated a central importance of
the FSCN1 promoter region 2219/+114, (that contains conserved
region A), in providing positive transcriptional regulation in
human carcinoma cells. We identified a commonality of regulatory
mechanisms between fascin-positive breast and colon carcinoma
cells and human fibroblasts that are constitutively fascin-positive.
This implies that fascin up-regulation in carcinomas is likely to be
mediated by aberrations in normal regulatory mechanism(s),
rather than activation of a novel mechanism. We note that the
basal low level of promoter reporter activity in SW1222 and T47D
Figure 6. CREB and AhR are specifically associated with the
2219/+7r e g i o no fFSCN1 in fascin-positive human colon
carcinoma cells. A, B, expression of AhR and CREB transcription
factors in human carcinoma cells. Whole cell extracts from the
equivalent of 4.5610
4 cells/lane were resolved on 10% SDS-PAGE gels
under reducing conditions, transferred to PVDF membrane and
immunoblotted with the indicated antibodies. C, D, detection of CREB
and AhR binding to the 2219/+7 region of the FSCN1 promoter by
chromatin immunoprecipitation from SW480 cells [C] or SW1222 cells
[D], as analysed on agarose gels. Sizes of markers are given in
nucleotides. E, Bar graph from qRT-PCR analysis showing the relative
fold enrichment of the 2219/+7 FSCN1 promoter region in test
immunoprecipitates relative to the control IgG immunoprecipitate,
which is assigned a value of 1. Values are the mean+/2SD from
duplicate reactions and 3 separate experiments.
doi:10.1371/journal.pone.0005130.g006
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these cells ([4] and Fig. 6A of this study). We considered that DNA
methylation might contribute to transcriptional repression of the
endogenous fascin-1 gene in these cells. However, no increase in
fascin protein was detected in SW1222 cells treated with the DNA
methylation inhibitor 5-azacytidine for up to 72 h (unpublished
observation). Other epigenetic mechanisms that would also be
deficient in the plasmid context include other histone modifica-
tions or effects of chromatin conformation [38].
These results can be contrasted with a previous study of the
activity of transcriptional regulatory elements in the FSCN1
promoter in human dendritic and monocyte cells. In this study,
FSCN1 promoter reporter activity also correlated with the natural
level of fascin protein in the cells; however, distinct transcriptional
regulatory mechanisms were identified in the different cell types
[26]. The FSCN1 promoter region 21600/2210 was found to
contain positive regulatory activity in mature dendritic cells,
whereas in monocytes or neuronal cells this region included
repressor activity [26]. The identification of repressor activity
within the region distal to 2210 is comparable with our study. No
transcriptional repressor proteins have yet been identified for the
FSCN1 promoter, although it is of interest that activation of liver X
receptor in lipopolysaccaride-matured dendritic cells reduces
fascin protein levels [39]. However, a general conclusion emerging
from the study with dendritic cells and our study is that, in all the
cell types examined in both studies, the region 2219/+114 has
major transcriptional activity.
The presence of candidate CREB- and AhR-binding motifs in
proximity to the FSCN1 transcriptional start site has been noted
[26], but the roles of these motifs or the relevant DNA-binding
transcription factors in promoter activity were not investigated
previously. Through unbiased methodologies for analysis of
sequence conservation within the 2219/+114 FSCN1 promoter
region, combined with experimental analysis of the effects of point
mutations on promoter reporter activity, we establish for the first
time that the CREB- and AhR-binding motifs each contribute
substantially to transcriptional activity of the FSCN1 promoter.
The combined mutation of both motifs inhibited promoter
reporter activity most strongly. We substantiated the concept of
a direct functional role for the CREB and AhR transcription
factors by the following novel findings: 1) both proteins are
physically associated with the 2219/+7 FSCN1 promoter region in
fascin-positive SW480 human colon carcinoma cells; 2), as
confirmed by qRT-PCR, these associations are not detectable in
fascin-negative SW1222 human colon carcinoma cells. It should
be noted that the chromatin immunoprecipitation method does
not identify the precise transcription factor binding site on the
DNA; additional approaches such as EMSA or use of promoter
decoys will be required to confirm this point. CREB binds as a
dimer to DNA and then recruits either CBP or p300 as a co-
activator of transcription [22]. CBP has been demonstrated to
impact the levels of fascin-1 transcript and protein in differentiating
NT2 neuronal cells and is thus a plausible candidate for a co-
activator of CREB on the FSCN1 promoter in SW480 cells [27].
Increased expression of CREB is correlated with high grade
prostate carcinomas [40], however, there are limited data on the
relationship between CREB expression and the progression and/
or metastasis of colon carcinomas. Mechanisms of CREB
activation are complex and involve cAMP-activated phosphory-
lation of CREB plus additional processes to generate signaling
specificity [32,41]. Thus, we consider it unlikely that there is a
simple relationship between levels of CREB, pCREB, and tumour
status. Interestingly, both CBP and p300 are frequently mutated in
colon cancer cell lines with microsatellite instability [42].
Figure 7. Analysis of b-catenin association with the FSCN1 promoter region in fascin-positive and –negative human colon carcinoma
cells. A, B, analysis of b-catenin binding to the 2219/+114 region of the FSCN1 promoter by chromatin immunoprecipitation from SW480 cells [A]
and SW1222 cells [B]. Immunoprecipitation with RNA polymerase II antibody was used as a positive control and is shown in each set. C, D, analysis of
b-catenin binding to the 22384/21412 region of the FSCN1 promoter by chromatin immunoprecipitation from SW480 cells [C] and SW1222 cells [D].
No specific association was detected.
doi:10.1371/journal.pone.0005130.g007
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proximal colon, which are the tumours that most frequently over-
express fascin [14,17]. We hypothesise that up-regulation of fascin
transcription in colon carcinomas might take place in conjunction
with altered regulation of the CREB complex. Further complexity
is indicated by our finding that AhR binding to the 2219/+7
FSCN1 promoter region also regulates promoter activity. AhR is
best known for its roles in pathways of metabolism of
environmental chemicals, such as dioxin, to toxic or carcinogenic
intermediates. Roles of AhR in the regulation of cell proliferation,
apoptosis, and cell adhesion and migration are now emerging [43].
These activities have been proposed to contribute to the
progression of mammary tumours [44]. Ligand-independent
AhR up-regulation has been documented in tumours and linked
with promotion of cell proliferation (e.g., [45]). Similar to CREB,
AhR functions in the context of transcriptional coactivators or
corepressors: it will be of future interest to identify the upstream
signaling mechanisms by which CREB and AhR binding to the
FSCN1 promoter are activated in carcinoma cells.
We also analysed the possible link between b-catenin signaling
and FSCN1 promoter activity. This pathway has been proposed
for a number of years but, to date, has only been analysed with
reference to the mouse fascin-1 promoter [3,8]. Under conditions
of active b-catenin signaling, b-catenin associates with DNA
through its interaction with LEF1/TCF DNA binding transcrip-
tion factors [28]. Although multiple candidate TCF binding sites
can be identified in the individual mouse or human fascin-1
promoter sequences ([3,8]; our observations), phylogenomic
analysis of conserved motifs demonstrates that, in fact, only
one TCF site is conserved between primates and mice. This site
is located at the proposed transcriptional start site (Fig. 1, motif 9
in Fig. 4A). Experimentally, we found that an inactivating point
mutation of this site altered 2219/+114 FSCN1 promoter
reporter activity in SW480 cells but did not affect promoter
activity in COS-7 cells. Furthermore, chromatin immunopre-
cipitation for b-catenin carried out in both fascin-positive and
negative- human colon carcinoma cells demonstrated that an
association of b-catenin with the endogenous 2219/+114
promoter region did not correlate with fascin protein levels.
The specificity of this result was confirmed by examination of a
more distal region containing a TCF binding motif conserved
between human, chimpanzee and dog, for which no specific
association of b-catenin was detected in either cell type. Overall,
these data do not support the hypothesis that b-catenin signaling
specifically regulates fascin expression in human carcinoma cells.
T h er o l eo fb-catenin in constitutive association with the FSCN1
promoter is unclear at this time. However, b-catenin has been
demonstrated to participate in transcription factor complexes
that include additional components, such as CBP/p300, that
exhibit both transcriptional repressor and activation properties
[46]: we speculate that such an alternative complex may
represent the context of b-catenin associated with the FSCN1
promoter.
Conclusion
We have identified that the conserved CREB and AhR binding
motifs within the promoter region of the fascin-1 gene are major
and specific determinants of transcriptional activity, and that the
association of these transcription factors with the corresponding
FSCN1 promoter region is specifically elevated in fascin-positive
human colon carcinoma cells. These novel findings will guide
further analysis of the environmental cues that activate aberrant
expression of fascin in early stage human carcinomas.
Materials and Methods
Cell lines and other materials
SW480 and SW1222 human colon adenocarcinoma cells, human
dermal fibroblasts (HDF) and COS-7 cells were cultured in DMEM
containing 10% fetal calf serum (FCS). MDA-MB-231 and T47D
human breast carcinoma cells were cultured in DMEM containing
5% FCS. All cells were maintained at 37uC in a humidified,
temperature- and CO2-controlled incubator. Mouse monoclonal
antibody to cAMP response element-binding protein (CREB)
(86B10) and rabbit monoclonal to phosphoCREB-S133-PO4
(87G3) were from Cell Signaling. Rabbit polyclonal IgG to CREB
used for chromatin immunoprecipitation was from Upstate. Rabbit
polyclonal IgG to AhR was from Santa Cruz. Mouse monoclonal
antibody to b-actin (AC-15) was from Sigma. Mouse monoclonal
antibody to fascin (55k-2) was from Dako. Mouse monoclonal
antibody to b-catenin (clone 14) was from BD Transduction Labs.
Non-immune rabbit or mouse IgG was from Sigma.
Bioinformatic analyses of the 59 flanking regions of
mammalian fascin-1 genes
Nucleotide sequences for 5.5 kb of DNA 59 to the ATG codon
of fascin-1 genes from six mammalian species were obtained from
the Entrez Genomes division of NCBI (http://www.ncbi.nlm.nih.
gov/sites/entrez/db=genomeprj). The sequences were from:
Homo sapiens [47], Build 36.2, chromosome 7; Pan troglodytes [48]
Build 2.1, chromosome 7; Macaca mulatta [49] Build 1.1,
chromosome 3; Canis lupus familiaris [50] Build 2.1, chromosome
6; Mus musculus [51] Build 37.1, chromosome 5 (5 86.0 cM), and
Rattus norvegicus [52] RGSC v3.4, chromosome 12.
DNA sequence conservation between the species was examined
by multiple sequence alignment of a 2 kb region 59 to the ATG
codon, using TCOFFEE Regular [53] at EMBnet (http://ch.
embnet.org/software/ClustalW-XXL.html). The sequences were
also analysed by the algorithm FootPrinter 3.0 (http://genome.cs.
mcgill.ca/cgi-bin/FootPrinter3.0/FootPrinterInput2.pl) that iden-
tifies short highly conserved regions, according to parsimony
criteria in combination with the use of established phylogenetic
relationships [29]. The motif size was set to 10 and a maximum
parsimony score of 2 was used. Candidate transcription factor
binding sites were identified in each sequence using Match 1.0
Public (http://www.gene-regulation.com/) with the algorithm set
to mimimise false negatives [54]. Match 1.0 uses a library of
mononucleotide position specific weight matrices from TRANS-
FACH 6.0 to predict candidate binding sites for specific
transcription factors [55]. Pairwise analyses were also made
through rVISTA 2.0 (http://rvista.dcode.org/) in which pairwise
sequence alignment is combined with analysis against the
TRANSFAC library of matrices to identify conserved candidate
transcription factor binding sites [56]. Because of the natural
variety of TCF-binding nucleotide sequences, candidate TCF
binding sites were also identified with the algorithm Target
Explorer [57] (http://luna.bioc.columbia.edu/Target_Explorer/)
using a customised position specific weight matrix based on a
library of motifs, compiled from a previous analysis of TCF
binding motifs [58] in combination with additional TCF motifs
from the literature, with the minimum threshold set to 4. All
results from the motif identification programmes were also
examined against the TCOFFEE and FootPrinter sequence
alignments.
Construction of promoter reporter plasmids
Firefly luciferase cDNA, the gift of Donna Driscoll, CCF, was
amplified by PCR with primers 294F/295R (Table S1). The PCR
Fascin-1 in Carcinoma Cell
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lian expression plasmid by the TOPO cloning method according
to manufacturer’s procedures (Invitrogen). This plasmid was
designated pcDNA3.1Luc. The BAC clone CTB-161C1 (Gen-
Bank AC006483), that contains 196416 bp of DNA from human
chromosome 7 including the region of FSNC1 in pBeloBAC11,
was from Invitrogen. BAC DNA was prepared with the QIAGEN
Large DNA construct kit and used as a template for PCR to
amplify portions of the 59 flanking region of FSCN1 using the
primer pairs listed in supplementary Table 1. The entire 3.1 kb 59
flanking region was sub-cloned into pcDNA3.1Luc by a multi-step
cloning procedure. First, the region 22952/2946 was amplified
with PCR primers 352F/369R, digested with BamHI and KpnI
and ligated into BamH1/KpnI digested pBS-SK. The region
21512/+114 was amplified with PCR primers 357F/353R,
digested with XcmI and KpnI and ligated 39 to the 22952/
21512 region in pBS-SK digested with XcmI/KpnI. The 3.1 kb
insert was digested from pBS-SK with BamHI and KpnI and
subcloned into pcDNA3.1Luc from which the CMV promoter
region had been removed by Bgl II/Kpn I digestion (Fig. 2;
designated pcFSCN-2952/+114Luc). pcFSCN1-1582/+114Luc
and pcFSCN1-219/+114Luc were generated by PCR with the
primers listed in supplementary Table 1, followed by HindIII/KpnI
digestion of the PCR product and ligation into correspondingly
digested pcFSCN-2952/+114Luc. For the internal promoter
deletion (D21582/250), PCR was carried out with primers
529F/530R, the product digested with AatII, and ligated in AatII-
digested pcFSCN-2952/+114Luc. pcFSCN1-50/+114Luc was pre-
pared by AatII digestion of pcFSCN-2952/+114Luc and self-
ligation. pcFSCN1-43/+114Luc was prepared by AatII digestion of
pcFSCN-2952/+114Luc, blunting of ends with T4 DNA polymer-
ase, and self-ligation. All sequences were checked by automated
DNA sequencing, carried out by CCF Genomics core facility.
Preparation of point mutations in the FSCN1 promoter
Sites for point mutation in the FSCN1 0.21 kb promoter region
were selected based on the bioinformatic analyses of candidate
transcription factor binding site core motifs and their conservation
in six mammalian species. The mutations were designed based on
known inactivating mutations of the motifs. All the designed
mutant nucleotide sequences were re-analysed in Match 1.0 Public
to check for loss of the specific transcription factor binding site and
that no new binding sites were generated. The CREB binding site
point mutant was based on previous inactivating mutations [59].
The TCF binding site point mutant was designed from the
FOPFLASH plasmid sequence [60]. All mutations were prepared
by PCR-based mutagenesis of the 0.21 kb promoter region in
pcDNA3.1Luc plasmid, using the QuickChange II XL Site-
directed mutagenesis kit (Stratagene) according to manufacturer’s
procedures and oligonucleotide primers as in supplementary Table
1. Sequences were confirmed by automated DNA sequencing of
the entire 0.21 kb promoter region.
Dual luciferase promoter reporter assay
1610
5 cells were plated per 14 mm well in 24-well plates for
24 hrs before transfection, with the exception of COS-7 cells that
were plated for 6 hrs. All cells were transiently co-transfected with
5.5610
214 moles of each FSCN1 promoter-luciferase reporter
construct and 0.034 mg of pRL-TK plasmid (Promega) using
PolyFect (QIAGEN) according to the manufacturer’s instructions.
pRL-TK encodes Renilla (sea-pansy) luciferase and provided an
internal control for transfection efficiencies. Appropriate amounts
of pBlueScript plasmid were included in the co-transfection to
maintain the total mass of DNA in each transfection at 0.34 mg.
After 24 h, cell lysates were prepared and transcriptional activities
measured using the Dual-luciferase reporter assay system accord-
ing to manufacturer’s instructions (Promega). Firefly and Renilla
luciferase activities were measured in a MLX luminometer
(DYNEX Technologies, Chantilly, VA). Relative firefly luciferase
activity was calculated by dividing the absolute activity of firefly
luciferase by the activity of Renilla luciferase. Within each cell line,
the normalised reporter activity of the CMV promoter was set as
1, and the activities of the FSCN1 reporter constructs expressed as
a fraction of the CMV activity. At least three independent
experiments were carried out for all cells and constructs, with
duplicate or triplicate samples in each experiment. Data were
analysed statistically by unpaired Student’s t-test.
Chromatin Immunoprecipitation
The protocol for chromatin immunoprecipitation was based on
the EZ-ChIP kit (Upstate) and manufacturer’s procedures, with
optimisation for the cell lines and antibodies tested. Briefly,
SW480 or SW1222 cells were seeded in 10 cm dishes for 48 hours
and protein-DNA complexes were cross-linked with 1% formal-
dehyde for 10 min. Cross-linking was quenched by addition of
125 mM glycine. Cells were washed with phosphate-buffered
saline, harvested, resuspended in 1% SDS, 10 mM EDTA,
50 mM Tris.HCl, pH 8.1, lysis buffer containing protease
inhibitors, and sonicated on ice by 6 pulses of 10 seconds duration
each at the 30% amplitude setting of a BRANSON Digital sonifier
(BRANSON, Danbury, CT). Soluble chromatin was collected by
centrifugation and an aliquot taken to represent the input fraction.
The remaining supernatant was incubated with 60 ml of protein
G-Sepharose (50% v/v slurry) under rotation for 1 h at 4uC for
pre-clearing. The supernatant was transferred to a new micro-
centrifuge tube, 4 mg of each antibody added with mixing for 5 h
at 4uC, of for the b-catenin antibody 2 mg was used and the
sample mixed overnight at 4uC. Protein G-Sepharose (40 mlo f
50% v/v slurry) was then added for 1 h with mixing at 4uC. Bead
pellets were washed for 5 min in 1 ml of low salt wash buffer, twice
in high salt wash buffer, once in lithium chloride wash buffer, and
twice in TE. Protein-DNA complexes were eluted in 200 mlo f
elution buffer and the cross-links reversed by overnight incubation
at 65uC. DNA was purified using QIAamp DNA mini kit
(QIAGEN) and eluted in 75 ml of 10 mM Tris.Cl, 0.5 mM
EDTA, pH 9.0. 4 ml aliquots were used as templates for PCR
amplification with primers 601F/603R (for CREB and AhR), or
353F/354R or 383F/384R (for b-catenin) and 449F/450R (for
GAPDH). Reactions were carried out with annealing at 58uC and
Hercules DNA polymerase (Stratagene) for 29 cycles. Reaction
products were analysed on 1.5% agarose gels or by quantitative
real-time PCR. Amplified DNAs were identified as the correct
genomic regions by DNA sequencing.
Quantitative real-time PCR
Reactions were performed on input DNA samples and DNA
from chromatin immunoprecipitations prepared from SW1222
and SW480 cells using the Express SYBR GreenER qPCR
SuperMix Universal (Invitrogen) and were run on an Prism 7000
instrument (Applied Biosystems) using 25 ml reaction volumes.
Cycling conditions were 50uC for 2 mins, 95uC for 2 mins,
followed by 40 cycles of 95uC for 15 sec and 60uC for 1 min. The
relative proportion of immunoprecipitated promoter fragments
was determined from the threshold cycle (C
T) for each PCR
reaction after normalization relative to input DNA. Fold
enrichment in the test immunoprecipitations was calculated as
two to the power [mean C
T value for that sample minus the mean
C
T value from the IgG control immunoprecipitation] and were
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by two-tailed t test.
Gel electrophoresis and immunoblotting
Whole cell lysates were prepared in SDS-PAGE sample buffer
buffer (2% SDS, 10% glycerol, 50 mM Tris-HCl, pH 6.8). All
samples were electrophoresed on 10% polyacrylamide gels under
reducing conditions and transferred to polyvinylidene difluoride
membranes(Millipore)usingasemidrytransferblotsystem.Blocking
and washing with Tris-buffered saline containing 1% Tween 20
(TBS-T), 2% skim milk powder and 0.5% bovine serum albumin
(Sigma)wasusedforallantibodiesexceptthepS133CREBantibody,
for which TBS-T containing 5% bovine serum albumin was used.
After incubation for 1 h with primary antibodies, or over-night with
the phospho-specific antibodies, blots were developed with alkaline
phosphatase-conjugated secondary antibodies and enhanced chemi-
luminescence (ECL) as described [61]. Quantitative analysis was
performed using NIH Image J version 1.38.
Supporting Information
Figure S1 TCOFFEE multiple sequence alignment of the 59
flanking region of the fascin-1 gene from six mammalian species.
2 kb of sequence was extracted from each of the indicated
genomes. Black shading indicates identical nucleotides, grey
shading indicates conservation in less than 50% of the sequences.
Sequences are numbered with reference to the transcriptional start
site as +1; in the human sequence the ATG codon is at +122.
Found at: doi:10.1371/journal.pone.0005130.s001 (0.27 MB
RTF)
Table S1 List of oligonucleotides used for PCR-based sub-
cloning, mutagenesis, or chromatin immunoprecipitation analysis.
Found at: doi:10.1371/journal.pone.0005130.s002 (0.02 MB
RTF)
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